Search results
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of...
NBC 10 - FOX 14 Monroe· 4 hours agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics ...
...NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA (NYSE:FIX), ...
Benzinga· 5 days agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™...
NBC 10 - FOX 14 Monroe· 5 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with ...
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
Clinical Trials Arena via Yahoo Finance· 5 hours agoUproleselan demonstrated encouraging preliminary efficacy and safety as a frontline combination with...
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program...
CW39 NewsFix· 1 day agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst ...
Earnings call: Enanta Pharmaceuticals Q2 fiscal results and pipeline updates By Investing.com
Investing.com· 23 hours agoEnanta Pharmaceuticals (NASDAQ: NASDAQ:ENTA), a biopharmaceutical company focused on developing oral...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 6 days agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 6 days agoThe treatment, Elahere (mirvetuximab soravtansine), is for patients with late-stage disease who have...
Most RA Patients Meet EMA's JAK Inhibitor Warning Criteria
Medscape· 5 days agoRecent regulatory warnings could mean that four in five patients with RA may not be prescribed JAK...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoNew York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie